title: The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians.
abstract: Since the arrival of several new antivirals and due to the growing molecular and clinical knowledge of hepatitis B virus (HBV) infection, therapy of hepatitis B has become complex. Clinical guidelines aim at streamlining medical attitudes: in this respect, the European Association for the Study of the Liver (EASL) recently issued clinical practice guidelines for the management of chronic hepatitis B. Guidelines made by international experts need however to be adapted to local health care systems. Here, we summarise the EASL guidelines with some minor modifications in order to be compatible with the particular Swiss situation, while discussing in more detail some aspects. Chronic hepatitis B is a complex disease with several phases where host and viral factors interact: the features of this continuous interplay need to be evaluated when choosing the most appropriate treatment. The EASL guidelines recommend, as first-line agents, using the most potent antivirals available with the optimal resistance profile, in order to abate HBV DNA as rapidly and as sustainably as possible. Once therapy has been started, the infection evolves and resistant viral strains may emerge. Rescue therapy needs to be started early with more potent agents lacking cross-resistance.
authors.affiliation: Division of Gastroenterology and Hepatology, Geneva University Hospitals, 4 rue Perret-Gentil, Geneva, Switzerland.
authors.forename: Florian
authors.initials: F
authors.lastname: Bihl
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Alaei
authors.forename: Francesco
authors.initials: F
authors.lastname: Negro
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D004351:Drug Resistance; D005260:Female; D015658:HIV Infections; D006282:Health Personnel; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000503:physiopathology / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D008103:Liver Cirrhosis / Q000517:prevention & control; D008297:Male; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011247:Pregnancy; D013557:Switzerland
chemical_list: D000998:Antiviral Agents